

Structured Product Details

NameELKS linked to MetLife, Inc.Issue Size\$74.32 millionIssue Price\$10Term6 MonthsAnnualized Coupon10.00%

Pricing Date	October 25, 2010
Issue Date	October 28, 2010
Valuation Date	April 15, 2011
Maturity Date	April 20, 2011
Issuer	Citigroup
CDS Rate	74.57 bps
Swap Rate	0.44%
Reference Asset	MetLife, Inc.'s stock
Initial Level	\$40.16
Conversion Price	\$40.16
Trigger Price	\$32.13
Dividend Rate	1.83%
Implied Volatility	34.02%
Delta ¹	0.46
Fair Price at Issue	\$9.66
Realized Return	11.00%
	17316G768 ww.sec.gov/Archives/edgar/ 9312510238088/d424b2.htm

Structured Products Research Report

Report Prepared On: 10/25/12

ELKS linked to MetLife, Inc.

Description

Citigroup issued \$74.32 million of ELKS linked to MetLife, Inc. on October 28, 2010 at \$10 per note.

These notes are Citigroup-branded reverse convertibles. These notes pay periodic interest coupons and at maturity convert into shares of MetLife, Inc.'s stock, if the closing price of MetLife, Inc.'s stock was ever below \$32.13 during the term of the notes. Similar securities are issued by other companies under different brand names.


These 6-month notes pay monthly coupons at an annualized rate of 10.00%. In addition to the monthly coupons, at maturity on April 20, 2011 investors will receive the market value of 0.25 share of MetLife, Inc.'s stock if during the term of the notes MetLife, Inc.'s stock ever closed at or below \$32.13—80% of MetLife, Inc.'s \$40.16 closing price on October 25, 2010. Otherwise, investors will receive the \$10 face value per note. In either case, investors receive the final coupon payment at maturity.

Valuation

This Citigroup ELKS linked to MetLife, Inc. can be valued as a combination of a note from Citigroup, a short down-and-in at-the-money put option, and a long down-and-in at-the-money call option on MetLife, Inc.'s stock. For reasonable valuation inputs this note was worth \$9.66 per \$10 when issued on October 28, 2010 because investors were effectively being paid only \$0.44 for giving Citigroup options which were worth \$0.79.

There is no active secondary market for most structured products. Structured products, including this note, therefore are much less liquid than simple stocks, bonds, notes and mutual funds. Investors are likely to receive less than the structured product's estimated market value if they try to sell the structured product prior to maturity. Our valuations do not incorporate this relative lack of liquidity and therefore should be considered an upper bound on the value of the structured product.

Payoff Curve at Maturity



The payoff diagram shows the final payoff of this note given MetLife, Inc.'s stock price (horizontal axis). For comparison, the dashed line shows the payoff if you invested in MetLife, Inc.'s stock directly.

Related Research

Research Papers:

www.slcg.com/research.php

- "Are Structured Products Suitable for Retail Investors?" December 2006.
- *"Structured Products in the Aftermath of Lehman Brothers,"* November 2009.
- "What TiVo and JP Morgan Teach Us about Reverse Convertibles," June 2010.

Tim Dulaney, Ph.D., Senior Financial Economist, SLCG (+1) 703.539.6777 TimDulaney@slcg.com


> FIND SLCG STRUCTURED PRODUCTS RESEARCH AT www.SLCG.com

© 2012 SECURITIES LITIGATION & CONSULTING GROUP. ALL RIGHTS RESERVED. 3998 FAIR RIDGE DRIVE, SUITE 250, FAIRFAX, VA 22033 | MAIN (703) 246-9380 | INFO@SLCG.COM 100 WILSHIRE BLVD, SUITE 950, SANTA MONICA, CA 90401 | MAIN (310) 917-1075

Principal Payback Table

MetLife, Inc.'s Stock	Converted Note Payoff	Non-Con- verted Note Payoff
\$0.00	\$0.00	
\$4.02	\$1.00	
\$8.03	\$2.00	
\$12.05	\$3.00	
\$16.06	\$4.00	
\$20.08	\$5.00	
\$24.10	\$6.00	
\$28.11	\$7.00	
\$32.13	\$8.00	\$10.00
\$36.14	\$9.00	\$10.00
\$40.16	\$10.00	\$10.00
\$44.18	\$11.00	\$10.00
\$48.19	\$12.00	\$10.00
\$52.21	\$13.00	\$10.00
\$56.22	\$14.00	\$10.00
\$60.24	\$15.00	\$10.00

Maturity Payoff Diagram




The contingent payoffs of this ELKS.

Analysis


The 10.00% annualized coupon rate is higher than the yield Citigroup paid on its straight debt but, in addition to Citigroup's credit risk, investors bear the risk that, at maturity, they will receive shares of MetLife, Inc.'s stock at precisely the time when these shares are worth substantially less than the face value of the note.

Investors purchasing ELKS effectively sell down-and-in put options to Citigroup, buy down-and-in call option, and post the note's issue price as collateral to secure satisfaction of the investors' obligations under the option contracts. Investors are compensated by Citigroup through "coupon" payments that represent partial payment for the premium difference of put and call options as well as interest on the investors' posted collateral. This ELKS is fairly priced if and only if the excess of the reverse convertible's "coupon rate" above the interest Citigroup pays on its straight debt equals the net value of the put and call options investors are exchanging with Citigroup. Whether the purchase of this ELKS is suitable or not is identically equivalent to whether selling put options on the reference asset at the option premium being paid by the brokerage firm was suitable for the investor in question.


Citigroup's Stock Price



The graph above shows the adjusted closing price of the issuer Citigroup for the past several years. The stock price of the issuer is an indication of the financial strength of Citigroup. The adjusted price shown above incorporates any stock split, reverse stock split, etc.



Credit default swap (CDS) rates are the market price that investors require to bear credit risk of an issuer such as Citigroup. CDS rates are usually given in basis points (bps). One basis point equals 0.01%. Higher CDS rates reflect higher perceived credit risk, higher required yields, and therefore lower market value of Citigroup's debt, including outstanding ELKS. Fluctuations in Citigroup's CDS rate impact the market value of the notes in the secondary market.




MetLife, Inc.'s Stock Price

The graph above shows the historical levels of MetLife, Inc.'s stock for the past several years. The final payoff of this note is determined by MetLife, Inc.'s stock price at maturity. Higher fluctuations in MetLife, Inc.'s stock price correspond to a greater uncertainty in the final payout of this ELKS.

Realized Payoff


This note matured on April 20, 2011 and investors received \$10.00 per note.

Reference Asset MetLife, Inc.'s Stock's Implied Volatility



The annualized implied volatility of MetLife, Inc.'s stock on October 25, 2010 was 34.02%, meaning that options contracts on MetLife, Inc.'s stock were trading at prices that reflect an expected annual volatility of 34.02%. The higher the implied volatility, the larger the expected fluctuations of MetLife, Inc.'s stock price and of the Note's market value during the life of the Notes.

Decomposition of this ELKS



This note can be decomposed into different components, and each component can be valued separately. The chart above shows the value of each component of this ELKS.

- Delta measures the sensitivity of the price of the note to the MetLife, Inc.'s stock price on October 25, 2010.
 CDS rates can be considered a measure of the probability that an issuer will default over a certain period of time and the likely loss given a default. The lower the CDS rate, the lower the default probability. CDS rate is given in basis points (1 basis point equals 0.01%), and is considered as a market premium, on top of the risk-free rate, that investors require to insure against a potential default.
 Fair price evaluation is based on the Black-Scholes model of the MetLife, Inc.'s stock on October 25, 2010.
 Calculated payout at maturity is only an approximation, and may differ from actual payouts at maturity.
 Our evaluation does not include any transaction fees, broker commissions, or liquidity discounts on the notes.

©2012 Securities Litigation and Consulting Group. All Rights Reserved. This research report and its contents are for informational and educational purposes only. The views and opinions on this document are those of the authors and should not be considered investment advice. Decisions based on information obtained from this document are your sole responsibility, and before making any decision on the basis of this information, you should consider whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. Investors should seek financial advice regarding the suitability of investing in any securities or following any investment strategies.